a phase ii trial of 6 months of alternating etoposide plus cisplatin ( ep ) and cyclophosphamide , vinblastine , actinomycin d , bleomycin , cisplatin ( vab-6 ) was conducted in 41 evaluable patients in an attempt to improve the treatment results in those patients considered to have `` '' poor-risk '' '' germ cell tumors ( gct ) .
C0078414
etoposide
C0008838
cisplatin